2005
DOI: 10.1007/s00280-005-0133-1
|View full text |Cite
|
Sign up to set email alerts
|

Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein

Abstract: Schisandrin A and B, and schisantherin A are potent P-gp inhibitor and is of potential for future clinical application.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
45
0

Year Published

2007
2007
2018
2018

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 56 publications
(47 citation statements)
references
References 11 publications
2
45
0
Order By: Relevance
“…15 In contrast, the efficacies of clinical chemotherapeutic agents such as taxanes, anthracyclines, vinca alkaloids, etc., were diminished significantly by these drug resistance factors. [16][17][18] The obvious question then is how does shikonin overcome drug resistance? First, shikonin induced cell death through a pathway distinct from apoptosis.…”
Section: Necroptotic Susceptibility Is a Weak Point Of Cancermentioning
confidence: 99%
“…15 In contrast, the efficacies of clinical chemotherapeutic agents such as taxanes, anthracyclines, vinca alkaloids, etc., were diminished significantly by these drug resistance factors. [16][17][18] The obvious question then is how does shikonin overcome drug resistance? First, shikonin induced cell death through a pathway distinct from apoptosis.…”
Section: Necroptotic Susceptibility Is a Weak Point Of Cancermentioning
confidence: 99%
“…This communication, combined with our previous reports [13,16,17,18,22,23], provides evidence that Sch B can protect Dox-induced acute and chronic cardiotoxicity and enhancing its anticancer activity.…”
Section: Discussionmentioning
confidence: 79%
“…Therefore, the development of novel potent, but non-toxic anti-cancer reagents is worth a continuous effort. In the last decade, dibenzocyclooctadiene lignans (e.g., deoxyschisandrin, γ -schisandrin, schisandrin C, schisandrin, gomisin A, schisantherin A) (He et al, 1997) has attracted considerable attention as a potential anti-cancer drug or an adjuvant to the conventional therapeutic modalities for human hepatocellular cancer (Wu et al, 2004;Pan et al, 2006;Li et al, 2007). The present study was undertaken to assess the antitumor activity of schisandrin C against three established human cancer cell lines.…”
Section: Discussionmentioning
confidence: 99%
“…First of all, dibenzocyclooctadiene lignans were reported to reverse cancer drug resistance by targeting P-gp (Pan et al, 2006), MRP1 (Li et al, 2007), and enhancing apoptosis (Li et al, 2006). Schisandrin C as one of the important dibenzocyclooctadiene lignans may have similar activities; secondly, schisandrin C as a strong liver protective agent can prevent liver injuries (Kiso et al, 1985) and inhibit lipid peroxidation (Lu & Liu, 1991;Liu & Lesca, 1982); finally, its activities on enhancement of mitochondrial glutathione antioxidant system and the induction of heat shock protein 70 (Ip et al, 1997).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation